City Therapeutics

Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise CAMBRIDGE, MA, May 27, 2025 – Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future

Viking Global Investors and Sofinnova Investments join a strong syndicate of existing investors including ARCH Venture Partners, Fidelity Management & Research Company and Invus Proceeds to accelerate the company’s RNAi engineering platform and pipeline, including ongoing Phase 1 clinical

Company plans to initiate a Phase 1 study in early 2026 with initial human data expected late 2026 Company’s first clinical-stage program headlines a diverse and novel pipeline poised to deliver 1-2 new investigational drugs into the clinic annually CAMBRIDGE, MA, November 10, 2025 – City T

City Therapeutics is a clinical-stage biotechnology company developing RNAi therapeutics designed to silence disease-relevant proteins, with the aim of providing meaningful and durable benefits for patients.

CITY THERAPEUTICS, INC. describes its privacy practices and how it handles information that identifies individuals, including personal information collected through its website and other activities covered by the policy.

City Therapeutics raises $99.5 million in Series B financing to advance its preclinical pipeline and expand its RNAi engineering platform. The Cambridge biotechnology firm is developing RNA interference therapies, and the funding targets both its pipeline and its engineering platform.

Jun 2026BioPharma DiveNews article

City Therapeutics presents preclinical data on CITY-RBP4, its next-generation investigational RNAi therapy for Stargardt disease, at the ARVO 2026 Annual Meeting. The data demonstrate ocular tissue delivery and RBP4 knockdown in animal models.

May 2026City TherapeuticsNews article

City Therapeutics submits a Clinical Trial Application for CITY-FXI, an investigational RNAi therapeutic targeting hepatic Factor XI. The submission advances the company’s first clinical-stage program, which is intended to treat thromboembolic diseases.

Nov 2025City TherapeuticsNews article

Biogen and City Therapeutics enter a strategic research collaboration to develop select novel, next-generation RNA interference (RNAi)-based therapies. The collaboration is worth up to approximately $1 billion, with $16 million upfront and $46 million in initial committed payments.

May 2025City TherapeuticsNews article